Posted on 11.18.24
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
Posted on 10.11.24
Siren CEO & Founder Dr. Nicole Paulk honored as one of the Most Influential Women in Bay Area Business
Posted on 8.9.24
Unveiling the critical pathways in AAV potency evaluation and future trends in gene therapy